Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRRONASDAQ:OGINASDAQ:PBYINASDAQ:VACC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRROKorro Bio$18.40+3.7%$18.76$11.13▼$98.00$172.76M2.3196,381 shs69,677 shsOGIOrganigram$1.14-1.7%$1.06$0.85▼$2.11$143.95M1.1706,441 shs220,786 shsPBYIPuma Biotechnology$3.08-3.1%$3.12$2.23▼$5.26$152.80M1.34442,043 shs228,853 shsVACCVaccitech$1.12+12.0%$1.57$1.64▼$5.10$43.17M-0.4244,643 shs39,864 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRROKorro Bio+6.48%-1.17%+1.95%-48.07%-68.74%OGIOrganigram+1.75%+7.41%+14.85%-25.16%-45.28%PBYIPuma Biotechnology+4.61%+4.95%+7.43%+4.61%-37.28%VACCVaccitech+19.18%+32.38%-4.77%+5.25%-61.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRROKorro Bio1.4843 of 5 stars3.60.00.00.02.70.00.6OGIOrganigram0.832 of 5 stars0.03.00.00.02.60.01.3PBYIPuma Biotechnology3.8111 of 5 stars3.52.00.00.01.93.33.1VACCVaccitechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRROKorro Bio 3.25Buy$114.63522.96% UpsideOGIOrganigram 3.00BuyN/AN/APBYIPuma Biotechnology 3.00Buy$7.00127.27% UpsideVACCVaccitech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VACC, PBYI, KRRO, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/19/2025KRROKorro BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.002/28/2025PBYIPuma BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRROKorro Bio$2.27M76.07N/AN/A$21.19 per share0.87OGIOrganigram$166.12M0.87N/AN/A$1.83 per share0.62PBYIPuma Biotechnology$230.47M0.66$0.74 per share4.19$1.12 per share2.75VACCVaccitech$13.42M3.22$0.06 per share19.30$6.52 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRROKorro Bio-$81.17M-$9.39N/AN/AN/AN/A-50.25%-38.48%5/13/2025 (Estimated)OGIOrganigram-$33.39M-$0.38N/AN/AN/A-31.69%-8.59%-6.54%5/13/2025 (Estimated)PBYIPuma Biotechnology$21.59M$0.616.428.11N/A9.56%41.60%10.71%5/8/2025 (Estimated)VACCVaccitech$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/ALatest VACC, PBYI, KRRO, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KRROKorro Bio-$2.60N/AN/AN/A$0.13 millionN/A5/13/2025Q2 2025OGIOrganigram-$0.03N/AN/AN/A$61.27 millionN/A5/8/2025Q1 2025PBYIPuma Biotechnology$0.02N/AN/AN/A$44.55 millionN/A3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 million2/27/2025Q4 2024PBYIPuma Biotechnology$0.10$0.39+$0.29$0.39$52.50 million$59.10 million2/11/2025Q1 2025OGIOrganigram-$0.03-$0.05-$0.02-$0.14$48.94 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRROKorro BioN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/AVACCVaccitechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRROKorro BioN/A11.2311.23OGIOrganigramN/A3.361.85PBYIPuma Biotechnology0.461.421.40VACCVaccitechN/A15.2615.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRROKorro Bio13.18%OGIOrganigram34.63%PBYIPuma Biotechnology61.29%VACCVaccitech26.13%Insider OwnershipCompanyInsider OwnershipKRROKorro Bio5.40%OGIOrganigram0.09%PBYIPuma Biotechnology23.70%VACCVaccitech6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRROKorro Bio709.39 million8.86 millionNo DataOGIOrganigram860126.27 million126.10 millionOptionablePBYIPuma Biotechnology20049.61 million37.45 millionOptionableVACCVaccitech3338.55 million36.23 millionNot OptionableVACC, PBYI, KRRO, and OGI HeadlinesRecent News About These CompaniesVTP-500 by Barinthus Biotherapeutics for Middle East Respiratory Syndrome (MERS): Likelihood of ApprovalDecember 31, 2024 | pharmaceutical-technology.comReal-World Data on the RSV Vaccine for Older AdultsNovember 12, 2024 | msn.com10 Startups Founded Out Of Oxford UniversityNovember 5, 2024 | techround.co.ukNigeria: Ten Things to Know About New R21 Malaria Vaccine Nigeria ReceivedOctober 18, 2024 | allafrica.comTen things to know about new R21 malaria vaccine Nigeria receivedOctober 18, 2024 | premiumtimesng.comBarinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trialsOctober 2, 2024 | finance.yahoo.comBuy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic AdvancesOctober 1, 2024 | markets.businessinsider.comBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerOctober 1, 2024 | markets.businessinsider.comStrong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B TherapiesSeptember 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical AdvancementsAugust 12, 2024 | markets.businessinsider.comBRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comGiving RSV and Flu Vaccines Together Led to Adequate Immune ResponsesAugust 7, 2024 | medpagetoday.comHow real are the threats to the US dollar?July 31, 2024 | uk.finance.yahoo.comZoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's GrowthJuly 29, 2024 | finance.yahoo.comGoogle invests in UK vaccine pioneer VaccitechJuly 26, 2024 | pharmaphorum.comBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024May 22, 2024 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical TrialsMay 17, 2024 | markets.businessinsider.comReal reasons Nigeria still missing out on malaria vaccine rolloutMay 11, 2024 | premiumtimesng.comChutes & Ladders—BridgeBio oncology execs take the reins of new spinoutMay 3, 2024 | fiercebiotech.comNews - Leon HooftmanMay 1, 2024 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVACC, PBYI, KRRO, and OGI Company DescriptionsKorro Bio NASDAQ:KRRO$18.40 +0.65 (+3.66%) Closing price 04:00 PM EasternExtended Trading$18.41 +0.01 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Organigram NASDAQ:OGI$1.14 -0.02 (-1.72%) Closing price 04:00 PM EasternExtended Trading$1.12 -0.02 (-1.75%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Puma Biotechnology NASDAQ:PBYI$3.08 -0.10 (-3.14%) Closing price 04:00 PM EasternExtended Trading$3.08 0.00 (-0.16%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Vaccitech NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
